Shares of Revolution Medicines (RVMD), which advanced 29% during regular trading to $102.71 after The Wall Street Journal reported earlier that AbbVie (ABBV) was in “advanced” takeover talks, has pulled back by 15% in after-hours to $87.71 after AbbVie (ABBV) said it’s not in talks to acquire the cancer drugmaker.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- AbbVie tells Bloomberg not in talks to buy Revolution Medicines
- AbbVie says not in discussions with Revolution Medicines, Reuters reports
- Erasca up 66% after WSJ report on AbbVie interest in Revolution Medicines
- Revolution Medicines extends gain to 29% after resuming trading
- Revolution Medicines trading resumes